

## **JOAN HAYWOOD, R.Ph.**

---

### **PROFESSIONAL EXPERIENCE**

2007 – present

**SNBL Clinical Pharmacology Center, Inc.**  
Pharmacy Manager

2005 - 2007

**University of Maryland, School of Pharmacy**  
Staff and Research Pharmacist

1985- 2005

**VA Maryland Health Care System, Pharmacy Service**  
Research Pharmacist

1981 - 1985

**University of Maryland Hospital, Oncology Pharmacy Service**  
Clinical Staff Pharmacist

1979 – 1981

**Union Memorial Hospital**  
Part-time Pharmacy Technician

1981

**University of Maryland, School of Pharmacy**  
Part-time Teacher's Aid

1975 - 1979

**Northern Pharmacy and Medical Equipment**  
Part-time Pharmacy Technician

### **EDUCATION**

1984 - 1985

**Graduate student**, University of Maryland

1978 - 1981

**Bachelor of Science**, University of Maryland

1975 - 1978

**Pre-pharmacy**, University of Maryland

## **PROFESSIONAL LICENSURE**

- Maryland Board of Pharmacy, NO. 09639, 1981

## **PROFESSIONAL AFFILIATIONS & MEMBERSHIPS**

- American Society of Hospital Pharmacists, 1978 — present
- Maryland Society of Hospital Pharmacists, 1978 — present
- Committee Report Editor, MSHP Newsletter, 1982-1983
- Kappa Psi Pharmaceutical Fraternity, 1978 — present
- Student American Pharmaceutical Association, 1978 — 1981
- Maryland Pharmaceutical Association, 1978 — 1982

## **PUBLICATIONS**

- Schreiber, Joan M., Intravenous Acyclovir, MSHP Newsletter, February 1983.
- Engstrom, Christine, Hernandez, Iris, Haywood, Joan, Lilenbaum, Rogerio, The Efficacy and Cost Effectiveness of New Antiemetic Guidelines, Oncology Nursing Forum, October 1999

## **PRESENTATIONS**

- Engstrom, Christine, Hernandez, Iris, Haywood, Joan, Lilenbaum, Rogerio, A Clinical Outcomes Study; The Efficacy and Cost Effectiveness of New Anti-Emetic Guidelines, Oncology Nursing Society, 22' Annual Congress, May 1997
- Haywood, Joan, Promoting and Advancing Clinical Research Through the Implementation of The Role of the Research Nurse Liaison, Role and Responsibilities of the Research Pharmacist, June 2004

## **RESEARCH EXPERIENCE**

### **2009**

- A Phase 1 Double-Blind, placebo-controlled, single-center dose escalation study to evaluate the safety and tolerability and pharmacokinetics of intramuscular administration of a new oxime
- A Phase I, Double-blind Crossover Study of the Acute Tolerability of Immediate Extended Administration of Methotrexate in Normal Healthy Volunteers.
- A Longitudinal Study in healthy Adult Volunteers Aged 18 to 85 Years to Describe Antibody Levels to Antigens Expressed by Staphylococcus aureus and  $\beta$ -Hemolytic Streptococci Species, and to Describe Carriage of These Bacteria
- A Phase 2a Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of a Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (recombinant) in Healthy Adults

- An open label, single dose, randomized, active controlled, two-period, two-sequence crossover pharmacokinetics study to assess the bioequivalence of the XXXX, a XXXX transdermal formulation versus Emsam 12mg/ day after a single dose in healthy volunteers.
- A phase 1 open label placebo controlled multiple dose study to evaluate the pharmacokinetics of XXXX for injection dosed twice and three times daily in healthy subjects.
- A Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Effects of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women.
- A Phase I, Open Label, PET Study in Healthy Subjects Following a Single Oral Dose of XXXX
- An in vivo Positron Emission Tomography study of the XXXX in healthy subjects, in patients with Schizophrenia.
- A placebo-controlled, ascending multiple-dose study to evaluate the safety and pharmacokinetics of XXXX in healthy subjects.
- An Open-Label Formulation Screening Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose and Multiple Doses of Delayed Release XXXX in Healthy Subjects.
- A randomized, open-label study to assess the effect of ketoconazole on XXXX pharmacokinetics and pharmacodynamics.
- A Randomized, Double-Blind, Sequential, Ascending Multiple Dose, Placebo Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX in Healthy Young Male Subjects.
- A Randomized, Double-Blind, Placebo Controlled Vaccination-Challenge Study of XXXX to Determine Efficacy Against the Symptoms of Moderate to Severe *Campylobacter jejuni* Infection in Normal Healthy Volunteers.
- Single dose pharmacokinetics and safety/tolerability of two formulations of XXXX transdermal systems compared to oral XXXX in healthy volunteers
- An open-label study to assess the effect of XXXX inducers on XXXX pharmacokinetics and pharmacodynamics
- Additional cohort - A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Rising Dose, Safety, Tolerability and Pharmacokinetic Study of XXXX When Administered to Normal Healthy Adult Volunteers
- A Three Part Study In Healthy Males and Females Assessing the Relative Bioavailability and Food Effect of Two Formulations of XXXX, the Estimated Bioavailability of XXXX, The Single and Repeat Dose Safety, Tolerability and Pharmacokinetics of Escalating Dose
- A randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Effects of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women.
- An open-label Phase I multiple dose trial to assess the safety, tolerability and efficacy of capsules containing cross-linked polyelectrolyte giving to ESRD patient.
- A 2-Period, 2-Panel, Double-Blind, Randomized, Placebo-Controlled Pilot Study of Experimental Models for the Assessment of the Perception of Potentially Injurious Heat in Household Settings After the Administration of XXXX in Healthy Subjects
- A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and Safety of XXXX When Compared With Valsartan and Olmesartan in Subjects with Essential Hypertension
- A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Rising Dose, Safety, Tolerability and Pharmacokinetic Study of XXXX When Administered to Normal Healthy Adult Volunteers
- A multiple-center, single-ascending dose, randomized, observer-blinded, placebo-controlled, study to investigate the safety, tolerability, and pharmacokinetics of XXXX following intravenous administration in individuals with allergic rhinitis.
- A Phase II Dose Finding Study with XXXX in Subjects with Recurrent Episodes of Genital Herpes

- An open label, randomized assessment of the relative bioavailability of a single dose of XXXX administered as a 15mg tablet, one 5 mg tablet or five 1 mg tablets compared with the 15 mg capsule and the effect of a high fat meal on the bioavailability of
- An open-label, dose escalating study to evaluate the safety of intravaginal oxybutynin in subjects with urge urinary incontinence

## 2007

- A placebo-controlled, ascending single-dose study to evaluate the safety and pharmacokinetics of XXXX in healthy subjects.
- An open-label, multiple-dose interaction study between XXXX and Metformin or Probenecid in healthy adult subjects.
- An open label, randomized assessment of the relative bioavailability of a single dose of XXXX administered as a 15mg tablet, one 5 mg tablet or five 1 mg tablets compared with the 15 mg capsule and the effect of a high fat meal on the bioavailability of the 15 mg tablet.
- A phase I open-label, single ascending dose study of the safety, nasal tolerability and pharmacokinetics of XXXX intranasal granisetron delivered by XXXX in healthy volunteers.
- A phase I, double-blinded study to evaluate the safety, tolerability, and immunogenicity of Pandemic Influenza plasmid DNA vaccines administered with the XXXX needle-free System.
- A two-period, open-label, randomized, crossover study to compare the steady state bioavailability of a Hhydrocodone/Deschlorpheniramine Polistirex extended-release suspension and a Hydrocodone Bitartrate/Dexchlorpheniramine Maleate immediate-release reference formulation healthy volunteers
- An in vivo Positron Emission Tomography study of the PDE4 Enzyme Occupancy by AVE8112 using XXXX in Healthy Subjects
- Randomized, single-center, open-label, 2-way crossover, 2-arm study with 3 treatments and 2 periods lasting 7 days each, minimum 7 day washout to determine the relative bioavailability of two XXXX Transdermal systems and to assess the wear characteristics of these systems
- Blood draw to obtain the PBMC layer of cells from whole blood from MS patients
- An in vivo Positron Emission Tomography study of the XXXX in healthy subjects, in patients with Alzheimer's Disease and in patients with Schizophrenia
- A Phase I, double-blind, placebo-controlled, randomized study to assess the safety, tolerability and pharmacokinetics of single escalating doses of XXX in healthy volunteers
- An open-label, non-randomized, one sequence, multi-center study to assess the effects of an oral contraceptive on the pharmacokinetics of XXXX in healthy female subjects
- A Pilot Single-Dose Study of the pharmacokinetics of two XXXX Fentanyl Transdermal Systems Compared to XXXX in Healthy Subjects.
- A Phase 1B, randomized, placebo-controlled clinical trial to study the safety and efficacy of xxx in Hepatitis C infected patients.
- Single-dose, randomized, three-period cross over design study of the XXXX compared with the XXXX.
- A randomized, double-blind, Phase III study of the efficacy and safety to XXXX in subjects requiring NSAID treatment.
- A Randomized, Double-Blind, Multiple-Site, Placebo Controlled, Parallel Design, Clinical Study to Evaluate the Bioequivalence of XXXX Compared to XXXX in Patients with Moderate to Severe Acne Vulgaris.
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study to Determine the Safety, Pharmacokinetic Effects, and Efficacy of XXXX in Patients with Hypercholesterolemia.
- A phase I study, assessing the pharmacokinetics of two formulations of Oxycodone and XXX compared with Oxycodone XXX consumed after chewing and with Oxycontin.
- A phase I study to evaluate the safety, tolerability and immunogenicity of the pandemic influenza vaccines XXXX and XXXX.
- A Phase II randomized, placebo-controlled clinical trial to study the safety and efficacy of XXXX in hepatitis C infected patients.

- Phase IIIa, 26 week, open-label, multi-center, randomized, parallel trial to investigate efficacy and safety of inhaled mealtime insulin with the XXXX plus XXXX versus XXXX in Type 2 Diabetes
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study Evaluating Pharmacokinetics and Safety of Anthrax Immune Globulin Intravenous (AIGIV).
- Single Dose Pharmacokinetics and Safety/Tolerability of Pramipexole Transdermal Systems Compared to Oral Pramipexole in Healthy Volunteers
- A Prospective, Multi-center Trial of XXXX Compared to Best Standard of Care in Patients with Progressive or Recurrent GBM.
- Efficacy and safety of 2 mg/day of XXXX on Sleep Maintenance Insomnia with a sub-study of the effect of XXXX on stable Type II Diabetes Mellitus: a one year, multi center, randomized, double-blind, placebo-controlled study.
- Multi-center, randomized, double-blind active controlled, parallel group study to investigate plasma folate, red blood cell folate and homocysteine levels during a 24 week oral administration of an OC containing folate compared to OC alone
- A 52-Week, Randomized, Double-Blind, Parallel-group, Multi-center, Phase IIIB Study Comparing the Long-term Safety of XXXX Actuations Twice Daily to XXXX Actuations Twice Daily in Adult and Adolescent African American Subjects with Asthma
- A 10 week Multicenter, randomized, double-blind, parallel-group, forced titration study using 24 hour ABPM to evaluate the efficacy of XXXX treatment regimen versus conventional treatment regimen with XXXX in patients with stage 2 hypertension
- A Multicenter, randomized, double-blind study to compare the efficacy and safety of patient-initiated XXXX to XXXX in immunocompetent adults with recurrent genital herpes
- A randomized, Double-Blind, Active-and Placebo-Controlled, Parallel- Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of XXXX Immediate-Release Formulation in Subjects Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease
- Analysis of protein or RNA Levels of the Glutamate Transporters, XXXX

### **1981-1985**

- Phase 1, 2, 3 studies in oncology treatment and supportive care.

### **1985-2005**

- Phase 1, 2, 3, 4 studies in oncology treatment and supportive care, infectious disease, cardiology, autoimmune diseases, substance abuse and psychiatry

### **2005-2007**

- Phase 3 studies in psychiatry